How Long Does Shingrix Protection Last?
Shingrix, the recombinant zoster vaccine for preventing shingles (herpes zoster) in adults 50 and older, provides strong protection that lasts at least 7-11 years based on clinical trials and follow-up studies, with efficacy remaining above 80% against shingles and 90% against postherpetic neuralgia (PHN) during that period.[1][2]
Initial phase 3 trials (ZOE-50 and ZOE-70) showed 97% efficacy in adults 50+ and 91% in those 70+ after one year, sustained at over 90% through year 4.[1] Longer-term data from ZOE-50 follow-up at year 7 reported 87.2% efficacy against shingles and 91.2% against PHN in adults 70+.[3] A 2023 analysis extended this to 11 years, with efficacy at 79.7% against shingles and 89.3% against PHN, indicating gradual waning but still robust protection.[2][4]
Does Protection Wane Over Time, and When?
Yes, efficacy declines modestly after peak levels. From years 7-11, it dropped from 90%+ to around 80% against shingles, though PHN prevention held stronger at 89%.[2] No breakthrough cases occurred in some cohorts up to 10 years, but real-world waning is expected beyond 11 years due to age-related immune decline.[4] The CDC notes protection is "likely long-lasting" but doesn't specify beyond 10 years, recommending vaccination regardless of prior shingles.[1]
Who Gets How Much Protection?
| Age Group | Peak Efficacy (Years 1-4) | Efficacy at 7 Years | Efficacy at 11 Years |
|-----------|---------------------------|---------------------|----------------------|
| 50-69 | 97% (shingles) | ~90% | Not fully reported |
| 70+ | 91% (shingles), 94% (PHN)| 87% (shingles), 91% (PHN) | 80% (shingles), 89% (PHN) [2][4] |
Younger recipients (50-69) show slightly higher and more sustained rates than those 70+.[3]
Real-World Duration vs. Trial Data
Real-world studies in the U.S. and Europe match trials: 86-92% effectiveness through 6-7 years post-vaccination.[5] A 2024 UK study found 76% effectiveness at 7-10 years.[6] Factors like immunosuppression reduce duration, dropping to 68% at 3 years in immunocompromised adults.[1]
Do You Need a Booster, and When?
No booster is currently recommended by CDC, ACIP, or GSK, as data show sufficient protection beyond a decade for most.[1][7] Trials continue to year 14; if waning accelerates, guidelines may update by 2027-2030.[4] Revaccination isn't advised yet, even after 10 years or shingles recurrence.
How Does Shingrix Compare to Zostavax for Duration?
Shingrix outperforms the older live vaccine Zostavax, which wanes to 50% efficacy by year 5 and <20% by year 10.[1][8] Zostavax is discontinued in the U.S.; Shingrix is now standard.
Sources
[1]: CDC Shingrix VIS
[2]: GSK 11-Year Efficacy Data
[3]: NEJM ZOE-50 7-Year Follow-Up
[4]: Vaccine Journal 2023 Analysis
[5]: CDC Real-World Effectiveness
[6]: UK Health Security Agency 2024
[7]: ACIP Recommendations
[8]: CDC Zostavax Comparison